Understand the source comparison
Kisspeptin vs Other Fertility Interventions: Where It Fits in the Treatment Hierarchy
Kisspeptin-54 Restores pulsatile GnRH secretion via GPR54 activation 10–20× increase in severe HH (clinical trial data) Yes. Enhances endogenous signaling Hypogonadotropic hypogonadism, hypothalamic amenorrhea, idiopathic oligozoospermia Most physiologically e
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Kisspeptin-54
- Restores pulsatile GnRH secretion via GPR54 activation
- 10–20× increase in severe HH (clinical trial data)
- Yes. Enhances endogenous signaling
- Hypogonadotropic hypogonadism, hypothalamic amenorrhea, idiopathic oligozoospermia
- Most physiologically elegant option for men with intact testicular function but suppressed central signaling. Limited by research-only availability
- hCG + FSH
- Directly replaces LH and FSH action at the testes
- 15–25× increase in HH (established therapy)
- No. Bypasses hypothalamus and pituitary
- Gold standard for HH, Kallmann syndrome
- Proven efficacy but requires frequent injections and doesn't address upstream dysregulation
- Clomiphene citrate
- Blocks estrogen receptors in hypothalamus, increasing endogenous GnRH
- 1.5–2× increase in secondary hypogonadism
- Yes. Stimulates endogenous pathway
- Secondary hypogonadism, low testosterone with preserved fertility
- Oral convenience but inconsistent response in men with severe oligozoospermia
- Testosterone replacement
- Suppresses LH/FSH via negative feedback
- Reduces sperm count to zero in most men
- No. Shuts down HPG axis entirely
- Low testosterone without fertility preservation goals
- Contraindicated for men attempting conception
- Varicocele repair
- Removes venous congestion and heat stress on testes
- 1.5–3× increase post-surgery
- N/A. Mechanical intervention
- Varicocele-associated oligozoospermia
- Only addresses anatomical cause. No hormonal effect
- Kisspeptin's position in the treatment hierarchy depends on the underlying cause of low sperm count. For men with HH or functional hypothalamic suppression (obesity, overtraining, chronic illness), kisspeptin represents the most mechanistically targeted intervention available. For men with primary testicular failure (Klinefelter syndrome, chemotherapy damage, cryptorchidism history), kisspeptin won't help because the problem isn't upstream signaling. It's gonadal capacity.
- Our assessment: kisspeptin is the ideal first-line research compound for men whose low sperm count stems from HPG axis dysregulation rather than testicular pathology, but it remains investigational and isn't available outside clinical trial enrollment or research peptide suppliers like Real Peptides.